Literature DB >> 3489480

Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.

A Rahman, A Joher, J R Neefe.   

Abstract

We have shown that doxorubicin entrapped in cardiolipin liposomes retain antitumour efficacy in mice but had diminished cardiac uptake and cardiotoxicity. Such liposomes are preferentially taken up by spleen. In a previous study we showed that a single dose of liposomal doxorubicin is not more toxic than free doxorubicin with regard to immunologic parameters including generation of cytotoxicity for histocompatibility alloantigens and mitogenic responsiveness. In the present study, we have explored clinically relevant multiple dosing at weekly intervals, 2, 3, or 4 times. Again, despite splenic localization of liposomal doxorubicin, the depressive effect on these immunological parameters is not greater than the effect of free drug, and, in addition, the damage is repaired earlier.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3489480      PMCID: PMC2001633          DOI: 10.1038/bjc.1986.190

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Pharmacokinetics of liposome-encapsulated antitumor drugs and implications for therapy.

Authors:  R L Juliano; D Stamp; N McCullough
Journal:  Ann N Y Acad Sci       Date:  1978       Impact factor: 5.691

2.  Treatment of Ewing's sarcoma with adriamycin (NSC-123127).

Authors:  R K Oldham; T C Pomeroy
Journal:  Cancer Chemother Rep       Date:  1972-10

3.  Adriamycin cardiotoxicity in man.

Authors:  J J Rinehart; R P Lewis; S P Balcerzak
Journal:  Ann Intern Med       Date:  1974-10       Impact factor: 25.391

4.  Clinical trials with adriamycin.

Authors:  E Middleman; J Luce; E Frei
Journal:  Cancer       Date:  1971-10       Impact factor: 6.860

5.  Phase I and preliminary phase II evaluation of adriamycin (NSC 123127).

Authors:  G Bonadonna; S Monfardini; M De Lena; F Fossati-Bellani; G Beretta
Journal:  Cancer Res       Date:  1970-10       Impact factor: 12.701

6.  In vitro and in vivo studies with adriamycin liposomes.

Authors:  E A Forssen; Z A Tökes
Journal:  Biochem Biophys Res Commun       Date:  1979-12-28       Impact factor: 3.575

7.  Role of host defense merchanisms in the antitumor activity of adriamycin and daunomycin in mice.

Authors:  A Mantovani; N Polentarutti; W Luini; G Peri; F Spreafico
Journal:  J Natl Cancer Inst       Date:  1979-07       Impact factor: 13.506

8.  Fate of a liposome-associated agent injected into normal and tumour-bearing rodents. Attempts to improve localization in tumour tissues.

Authors:  G Gregoriadis; D E Neerunjun; R Hunt
Journal:  Life Sci       Date:  1977-08-01       Impact factor: 5.037

9.  Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin.

Authors:  R L Juliano; D Stamp
Journal:  Biochem Pharmacol       Date:  1978-01-01       Impact factor: 5.858

10.  Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes.

Authors:  A Rahman; A Ganjei; J R Neefe
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more
  4 in total

1.  Novel drug delivery system using thermoreversible gelation polymer for malignant glioma.

Authors:  Takao Arai; Tatsuhiro Joki; Masaharu Akiyama; Miyuki Agawa; Yuichi Mori; Hiroshi Yoshioka; Toshiaki Abe
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

2.  Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes.

Authors:  M B Bally; R Nayar; D Masin; P R Cullis; L D Mayer
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Dye binding assay reveals doxorubicin preference for DNA versus cardiolipin.

Authors:  Colin A Fox; Robert O Ryan
Journal:  Anal Biochem       Date:  2020-02-08       Impact factor: 3.365

4.  Evaluation of triblock copolymeric micelles of δ- valerolactone and poly (ethylene glycol) as a competent vector for doxorubicin delivery against cancer.

Authors:  Lekha Nair K; Sankar Jagadeeshan; S Asha Nair; G S Vinod Kumar
Journal:  J Nanobiotechnology       Date:  2011-09-25       Impact factor: 10.435

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.